Soft Tissue Sarcoma Adult Clinical Trial
Official title:
Feasibility of Assessing Drug Response to Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Patients Undergoing Surgery.
This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
This is a single arm, pilot study designed to test the feasibility of using the CIVO (Comparative In Vivo Oncology) system in patients with soft tissue sarcoma accessible for percutaneous injection. Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected 4 to 72 hours prior to surgery using the CIVO device. Minute volumes (up to 8.3 microliters) of saline (negative control) or microdoses of anti-cancer agents will be percutaneously injected in a columnar fashion through each of 8 needles into a single solid tumor. Following the patient's biopsy surgery or tumor resection surgery, the injected portion and a small uninjected portion will be used to determine the in situ drug response in the tumor. None of the data from this evaluation will be shared with patients or used to make clinical decisions. Study clinicians will have access to the patient's health record for 1 year after the study to monitor patient treatment responses. Such information will be used to help evaluate the correlation between clinical response and tumor response assessed via CIVO. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04656262 -
Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients
|
Phase 3 | |
| Recruiting |
NCT03077178 -
Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over
|
N/A | |
| Not yet recruiting |
NCT06110650 -
A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma
|
N/A | |
| Terminated |
NCT03735758 -
Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib
|
Phase 4 | |
| Not yet recruiting |
NCT03951571 -
Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma
|
Phase 2 | |
| Not yet recruiting |
NCT06273852 -
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors
|
Early Phase 1 | |
| Enrolling by invitation |
NCT03134742 -
Radiation Effects on Bone
|
||
| Not yet recruiting |
NCT06252727 -
Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES)
|
Phase 1 | |
| Recruiting |
NCT04617327 -
Pre-operative RadiothErapy for Soft Tissue SarcOmas
|
N/A | |
| Recruiting |
NCT05116254 -
Sarcomas and DDR-Inhibition; a Combined Modality Study
|
Phase 1 | |
| Active, not recruiting |
NCT03526679 -
Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04008238 -
Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients
|
N/A | |
| Recruiting |
NCT04095208 -
Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study
|
Phase 2 | |
| Recruiting |
NCT04330456 -
Combined Treatment of Patients With Soft Tissue Sarcoma Including Preoperative Stereotactic Radiation Therapy and Postoperative Conformal Radiation Therapy
|
N/A | |
| Completed |
NCT03833037 -
Study of a Cohort of Cases of Synovial Sarcoma Treated in the Orthopedic Surgery and Traumatology Department of the Hospital de Sant Pau Between 1983 and 2016
|
||
| Recruiting |
NCT05961761 -
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
|
Phase 2 | |
| Recruiting |
NCT05182164 -
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
|
Phase 2 | |
| Withdrawn |
NCT03104335 -
Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial
|
Phase 2 |